lnc-POP1-1通过调控MCM5蛋白DNA修复活性增强口腔鳞癌细胞顺铂耐药的机制
批准号:
82103008
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
蒋英英
依托单位:
学科分类:
肿瘤治疗抵抗
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
蒋英英
中文摘要
DNA损伤修复导致的顺铂耐药是口腔鳞癌化疗失败的主要原因之一,而长链非编码RNA(lncRNA)在DNA损伤修复中的作用尚不明确。申请人前期从口腔鳞癌顺铂耐药细胞中筛选出表达上调但功能未知的核内lncRNA lnc-POP1-1;发现其与口腔鳞癌细胞顺铂耐药有关,并参与调控DNA损伤修复途径;进一步发现lnc-POP1-1与DNA修复相关蛋白MCM5结合,调控MCM5蛋白的表达。据此我们推测:lnc-POP1-1通过与MCM5蛋白相互作用调控MCM5蛋白稳定性和DNA修复活性来增强口腔鳞癌细胞顺铂耐药性。本项目拟通过CRISPR/Cas9、RNA pull-down、RIP、Co-IP等方法,从临床样本检测、实验动物学及分子生物学等层面系统阐述lnc-POP1-1调控口腔鳞癌顺铂耐药的具体机制。这将丰富我们对口腔鳞癌顺铂耐药的认知,同时为临床寻找顺铂耐药预测标记和逆转靶点提供新的研究基础。
英文摘要
Cisplatin resistance caused by DNA damage repair is one of the main reasons for the chemotherapy failure of oral squamous cell carcinoma (OSCC), and the role of long noncoding RNA (lncRNA) in DNA damage repair is still unclear. In our recent studies, the applicant screened a novel lncRNA named lnc-POP1-1 which was mostly localized in the nucleus and was upregulated in cisplatin-resistant OSCC cells, however, the function of lnc-POP1-1 was unknown. Our preliminary experiments found that lnc-POP1-1 was related to cisplatin resistance of OSCC cells and participated in DNA damage repair pathways. Furthermore, lnc-POP1-1 could bind to Minichromosome maintenance proteins 5 (MCM5) which was a DNA repair-related protein to upregulate the protein expression of MCM5. Based on the results of preliminary experiments, we propose the hypothesis that lnc-POP1-1 enhances cisplatin resistance of OSCC cells by interacting with MCM5 and regulating the stability and DNA repair activity of MCM5 protein. The purpose of this project is to systematically study the effect of lnc-POP1-1 on cisplatin resistance of OSCC from clinical tissue specimens, experimental zoology and molecular biology, and to clarify the mechanism of lnc-POP1-1 participating in DNA damage repair by the methods of CRISPR/Cas9 system, RNA pull-down, RNA Binding Protein Immunoprecipitation (RIP), Co-Immunoprecipitation (Co-IP), etc. This study will enrich the understanding of cisplatin resistance in OSCC, which provides a new experimental basis for identifying the predictive biomarkers and the reversed therapeutic targets for cisplatin resistance.
口腔鳞状细胞癌(简称口腔鳞癌)是口腔颌面部最常见的恶性肿瘤,因其局部复发率高,转移率高,预后差,严重影响人们生命健康和生活质量。顺铂作为一线化疗方案的核心药物以及首选放疗增敏剂在临床上被广泛使用;然而,顺铂耐药是导致口腔鳞癌患者治疗失败和不良预后的重要原因之一。不幸的是,目前仍缺乏有效的顺铂耐药预测标记物和逆转耐药靶点。本项目聚焦于长链非编码RN(lncRNA)调控口腔鳞癌顺铂耐药性的研究,揭示了lncRNA lnc-POP1-1与其上游分子VNIR5调控口腔鳞癌顺铂耐药的分子机制。具体研究结果包括:VN1R5与lnc-POP1-1在顺铂耐药细胞和组织中均高表达,体内外实验证实VN1R5和lnc-POP1-1的表达改变均显著影响口腔鳞癌细胞对顺铂的耐受性。进一步发现,VN1R5通过激活转录因子Sp1的转录活性来调控lnc-POP1-1的表达,且Sp1结合lnc-POP1-1启动子的特定区域。此外,lnc-POP1-1能够与MCM5蛋白特异性结合,参与DNA损伤修复过程。Lnc-POP1-1与MCM5的表达呈正相关,两者均分布于细胞核,lnc-POP1-1与MCM5的结合有助于MCM5在细胞核内的滞留,从而降低MCM5的泛素化水平和抑制其通过蛋白酶体途径的降解。最后体内外实验证实lnc-POP1-1与MCM5相互作用能够影响口腔鳞癌细胞的顺铂耐药性。由此我们得出如下结论:VN1R5通过cAMP/PKA信号通路增强转录因子Sp1的转录活性,进而上调lnc-POP1-1的表达;lnc-POP1-1与DNA修复蛋白MCM5结合,减缓其泛素化降解,参与DNA修复途径,从而增强口腔鳞癌细胞对顺铂的抗性。研究结果为评价lnc-POP1-1和VN1R5能否成为口腔鳞癌顺铂耐药预测标记物提供实验依据。本研究不仅为口腔鳞癌顺铂耐药性的分子机制提供了新的见解,也为开发针对顺铂耐药性的新型治疗方法提供了潜在靶点和策略。
国内基金
海外基金